Jump to content

Search the Community

Showing results for tags 'Radium 223'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 8 results

  1. Cracker Video Jim - if this doesn't motivate members to start pressurizing their politicians -I don't know what will! Well done.
  2. Xofigo (radium 223) is a radioactive material that specifically targets bone metastases from prostate cancer. Xofigo (radium 223) is administered intravenously in hospital and is regarded as a medical service. This means that the application for it to be publicly funded must be made to the Medical Services Advisory Committee. The applications for new cancer drugs to be publicly funded are made to the Pharmaceutical Benefits Advisory Committee. According to Bayer, the manufacturer of Xofigo (radium 223), the policies that apply to listing on the Medical Benefits Schedule are different from the policies that apply to listing on the Pharmaceutical Benefits Scheme. April 2014 Recommendation that Xofigo be listed on the Medical Benefits Schedule. It has been more than 2 years since the Medical Services Advisory Committee recommended that Xofigo (radium 223) be listed on the Medical Benefits Schedule. Bayer disagreed with the proposed pricing arrangements that the Medical Services Advisory Committee recommended. What's happening now? Unfortunately, nothing. There appears to be a stalemate. A fellow Victorian sufferer with advanced prostate cancer has shared with me the copy of a recent letter that he has received from Bayer.
  3. With increasing options to treat advanced prostate cancer, there is no clear agreement on the order in which these treatments should be given. I attach a chart prepared (following the STAMPEDE clinical trial which recommended early ADT and chemotherapy for certain patients) by an American oncologist setting out his view of what is currently best clinical practice in America. In Australia our options are more restricted: Abiraterone and Enzalutamide are only available on the Pharmaceutical Benefits Scheme after chemotherapy and Provenge is not available on the Pharmaceutical Benefits Scheme. Oldtimer's Disease - I can't remember which publication I found this table in. A prize for anyone who can tell me where it came from.
  4. The Malecare Advanced Prostate Cancer Blog reported on research data presented at the 7th European Multidisciplinary Meeting on Urological Cancers held in Barcelona from 12-15 November 2015. Patients who were treated with abiraterone acetate (Zytiga) or denosumab at the same time as they were treated with Ra-223 had better Overall Survival. Patients who had a good ECOG performance status*, no pain and low alkaline phosphatase (ALP)# had significantly longer Overall Survival. * ECOG performance status Clinical trials require the use of standard criteria for measuring how the disease impacts a patient’s daily living abilities (known to physicians and researchers as a patient’s performance status). The ECOG Scale of Performance Status is one such measurement. It describes a patient’s level of functioning in terms of their ability to care for themself, daily activity, and physical ability (walking, working, etc.). The scale was developed by the Eastern Cooperative Oncology Group (ECOG). # Alkaline phosphatase (ALP) This is a protein that the body produces mainly in the liver and in bones. With prostate cancer, elevated levels of ALP are associated with the formation of metastases in the bones.
  5. http://tinyurl.com/pcwv6zd Information in the above reference indicates that the administration of Xofigo/Alpharadin/Radium 223 in company with abiraterone/Zytiga increased the effectiveness of Xofigo as well as overall survival. Combining EBRT (External Beam Radiation Therapy) with Xofigo increased likelihood of bone marrow failure.
  6. Paul Edwards

    Xofigo Update

    The US Federal Drugs Administration approved the use of Radium 223 (Brand name Xofigo also called Alpharadin) two years ago. The well-known US prostate oncologist Dr Mark Scholz gives an update on the experience of his clinic in using the drug. Click on this link to read his article. Xofigo is not yet available in Australia on the PBS
  7. Thanks to Chuck Maack for drawing our attention to the report of a recent presentation by Dr Oliver A Sartor who was the principal North American investigator for the clinical trial that led to the approval by the United States Food and Drug Administration (FDA) for radium 223 (brand name Xofigo). In 2013 the FDA approved radium 223 for treatment for patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. Dr Sartor said that determining whether or not a patient had symptoms of bone metastases could often be a grey area. He considered the extent of bone metastases was more important than the presence of pain in determining whether to treat a patient with radium 223. Dr Sartor was treating patients with metastatic castration-resistant prostate cancer who had a significant burden of bone-metastatic disease, even though they might not be considered symptomatic. After nearly a year of clinical use, Dr Sartor said that the optimal setting for radium 223 appeared to be in combination with new hormonal therapies such as Abiraterone (Xytiga) and Enzalutamide (Xtandi). At present a large multi-country Stage III clinical trial is about to start recruiting in Australia: Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms Dr Sartor said large clinical trials would be needed before radium 223 could be considered for use on patients who did not have metastatic disease or were not castration-resistant.
  8. Paul Edwards

    Xofigo (Radium 223) - Getting there

    At its April 2014 meeting the Medical Services Advisory Committee considered an application by Bayer to list Xofigo (radium 223) on the Medicare Benefits Schedule. Xofigo (radium 223) is a new drug which significantly increases life expectancy and quality of life for men with castration-resistant prostate cancer who have bone metastases. The advice to the Health Minister from the Medical Services Advisory Committee has now been made public. The good news is that the Medical Services Advisory Committee has recommended that Xofigo be supported for public funding and listed on the Medicare Benefits Schedule. However, the price for Xofigo recommended by the Medical Services Advisory Committee was not acceptable to Bayer. It's not uncommon for the Government to reject the initial price claimed by a drug company or for a drug company to reject the inital price offered by the Government Bayer is continuing to negotiate the price of the drug with the Government. Bayer said that it "hopes to resolve the outstanding issues...... and to provide Australian patients with access to the drug in a timely manner".
×